| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802599201022 | 259920102 | LEVITRA F.C.TAB 5MG/TAB BTx4 (σε BLISTERS) | 7.32 | 7.72 | 11.05 |
| 05/2018 | 2802599202012 | 259920201 | LEVITRA F.C.TAB 10MG/TAB BTx2 (σε BLISTERS) | 7.50 | 7.91 | 11.32 |
| 05/2018 | 2802599202029 | 259920202 | LEVITRA F.C.TAB 10MG/TAB BTx4 (σε BLISTERS) | 13.88 | 14.63 | 20.93 |
| 05/2018 | 2802599203019 | 259920301 | LEVITRA F.C.TAB 20MG/TAB BTx2 (σε BLISTERS) | 12.84 | 13.53 | 19.36 |
| 05/2018 | 2802599203026 | 259920302 | LEVITRA F.C.TAB 20MG/TAB BTx4 (σε BLISTERS) | 24.66 | 25.99 | 37.19 |
| 05/2018 | 2802599204030 | 259920403 | LEVITRA OR.DISP.TA 10MG/TAB BTx4 σε BLISTER ALU/ALU ALU/ALU | 19.18 | 20.22 | 28.93 |
Used for the treatment of erectile dysfunction
Vardenafil inhibits the cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by vardenafil enhances erectile function by increasing the amount of cGMP.
Symptoms of overdose include vision changes and back and muscle pain.
Vardenafil is rapidly absorbed with absolute bioavailability of approximately 15%.
4-5 hours
After oral administration, vardenafil is excreted as metabolites predominantly in the feces (approximately 91-95% of administered oral dose) and to a lesser extent in the urine (approximately 2-6% of administered oral dose).
* 208 L
* 56 L/h